Asaleadingbiotechcompanyfocusingexclusivelyonearlydrugdiscoveryanddevelopmentservices,GenScriptprovidesacomprehensiveportfolioofservicesthatincludeBio-Reagent,Bio-Assay,LeadOptimization,andAntibodyDrugDevelopment.

Dldevelop.comissupplierofbiologicalreagentsforthelifesciences.WespecializeintheproductionofELISAkits,productshavebeensoldworldwide.

WuhanUSCNBusinessCo.,Ltd.mainlyfocusedonmarketingoflifescienceassayreagents,SuchasProteins,AntibodiesandImmunoassayKits(ELISAKit,CLIAKit,ChipKit)

上海快序生物科技有限公司专注于基于质谱的蛋白质组学领域，运用人工智能和机器学习技术，开发了无需细胞系或DNA，直接对抗体蛋白质进行测序的技术（Antibodyproteindenovosequencing）。此项革命性技术不仅克服了传统蛋白测序技术的种种障碍和不足，大大提高了实验效率，并且在抗体工程，抗体药物研发等生物医学领域皆有广泛的应用。

Zeta-Life,Isaprofessionalengagedinlifescienceinstrumentsandreagentsagentsalesandservices,oneofthewell-knownenterprises.Ouragentathomeandabroadwell-knownbiotechnologyproducts,salesoftheinstruments,consumables,molecularandbiochemicalreagent,immunologicalreagentsandcellculturereagents,hasbeenwidelyusedinlifescienceresearch,developmentandapplication,pharmacy,diseasediagnosisandcontrol,populationandhealth,biologytechnologyfields.CustomersthroughouttheUniversity,ResearchInstitute,hospitals,healthandepidemicprevention,commodityinspectionandquarantine,pharmaceuticalcompanies,BiotechCorpandfoodindustryandotherunits.

博奥龙Biodragon是一家由留学归国人员创办的生命科学领域高新技术企业，专业从事新型生化试剂的研发和销售。包括QuickAntibody™免疫佐剂、QuickShuttle™转染试剂、QuickFreezing™细胞冻存液、QuickVerification™胶体金检测卡、HybridomaFeeder添加因子和Pan-HPV™HPVL1抗体等多种独特的自主知识产权产品

ISO13485:TotalIgEAntibodyAssayKit(ColloidalGold)

NatureBiosciences,Naturebios,荟丹生物,Antibody,mAb,RabbitmAb,ECLkit,Nature抗体，单抗,磷酸化抗体,抗体定制,抗体研发,试剂研发,NatureBiosciences,

上海靖亚生物科技有限公司（GenAsiaBiotechCo.,Ltd）是一家集研发、销售、实验技术服务于一体专注于生命科学和生物技术领域的高科技企业，主要产品ELISA试剂盒、CLIA试剂盒、Elisapot试剂盒，Protain蛋白、Antibody抗体等，共逾20000多个产品。GenAsia致力于提供生命科学领域的技术服务，提供Westernblot、ELISA、各类PCR等

Proteintechmatchesits’customers’dedicationtoresearchbyprovidinghigh-qualityantibodies,ELISAkitsandproteinsthatcontributetoreproducibleresults.Learnmorehere.

HarbourBioMed(HBMHoldings)isaglobalbiopharmaceuticalcompanycommittedtother&dandcommercializationofnovelantibodytherapeuticsinoncologyandimmunologicaldiseases.